Immunodeficiency 14
MONDO:0014222Also known as: Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS), immunodeficiency 14, immunodeficiency 14A, autosomal dominant, immunodeficiency type 14, Activated PI3K-Delta syndrome, IMD14, p110-Delta-Activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency
47 clinical trials for this condition and its sub-types, 6 tagged with Immunodeficiency 14 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug shows promise for Long-Term control of rare immune disorders
Disease control OngoingThis study is testing the long-term safety of a drug called leniolisib in people with primary immunodeficiency disorders linked to PI3K signaling. Participants are 12 people who already took leniolisib in a previous study and may benefit from continuing it. The goal is to see if …
Phase 2 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for kids with rare immune disease: leniolisib trial launches
Disease control OngoingThis study tests a drug called leniolisib in children aged 1 to 6 years who have a rare genetic immune disorder called APDS. The drug aims to control the overactive immune system and reduce swollen lymph nodes. Researchers will monitor safety and how well the drug works over time…
Phase 3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare immune disease: drug targets root cause
Disease control OngoingThis study tests a drug called leniolisib in children aged 4 to 11 with APDS, a rare genetic condition that causes a faulty immune system. The goal is to see if the drug is safe and can control the disease by blocking an overactive immune signal. About 15 children will take the d…
Phase 3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC